DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS IN Lithuania ONLY.
Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Lithuania.
Valstybinė vaistų kontrolės tarnyba prie Lietuvos Respublikos sveikatos apsaugos ministerijos
Tel.: 8 800 73568
El. paštas: [email protected]
Pranešimo forma pildymui internetu: https://vapris.vvkt.lt/vvkt-web/public/nrvSpecialist
Pranešimo forma skelbiama: https://www.vvkt.lt/index.php?1399030386
Contact Us
Tel: +370 5 214 1844
09:00 - 17:00
Monday - Friday